Biomesense Inc.
Chicago, IL
- UEI
- MUZ4XK1Q1L15
- CAGE
- 81U86
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 1452 E 53rd St, Chicago, IL 60615, USA
- Website
- biomesense.com
- Founded
- 2018
- Employees
- 1-10
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Envivo Bio Inc. | San Carlos, CA | — |
| Nexilico, Inc. | Danville, CA | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Holobiome, Inc. | Boston, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Vedanta Biosciences, Inc. | Cambridge, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Unlocked Labs Inc. | Laramie, WY | — |
About the company
Biomesense Inc. is a for-profit corporation registered to receive federal awards since February 2018. The company specializes in developing innovative biotechnology platforms and biosensors to advance microbiome research and accelerate investigations related to human health. Biomesense focuses on creating novel measurement technologies that enable large-scale, longitudinal studies of the gut microbiome, with applications in areas such as immunology, metabolism, neurodegenerative disease, cancer, and infectious disease. Their work aims to overcome critical barriers in microbiome research by providing tools for dense, time-longitudinal sampling of participants' gut microbiomes at low cost and with improved patient adherence.
Through federal grant awards, Biomesense Inc. has received funding to develop several cutting-edge technologies. In March 2024, they were awarded a $976,771 cooperative agreement from the National Science Foundation's Technology, Innovation, and Partnerships program to create a platform for measuring and analyzing microbial gene expression in the gut microbiome. This project involves refining RNA capture and storage processes, integrating them into an automated hardware system, and developing analytical methods for the resulting datasets. Previously, in June 2021, the company received an $883,212 project grant from the National Institutes of Health's National Center for Advancing Translational Sciences to develop a novel biosensor for accelerating gut microbiome investigations. This work focused on validating microbial lysis and DNA isolation functions of a prototype biosensor designed for home use. Additionally, in January 2021, Biomesense was awarded a $255,658 SBIR Phase I grant from the National Science Foundation to develop a portable, low-cost biosensor for rapidly detecting SARS-CoV-2 and analyzing gut microbiome composition from patient samples. These projects demonstrate Biomesense's commitment to creating innovative tools that can significantly advance microbiome research and potentially lead to new biomarkers, diagnostics, and therapeutics.
Quick answers
Is Biomesense Inc. registered in SAM.gov?
Yes. Biomesense Inc.'s SAM.gov registration is active through September 2, 2027.
What is Biomesense Inc.'s most recent federal award?
Biomesense Inc.'s most recent federal grant award is Sbir phase II: development of a novel measurement technology to enable longitudinal multiomic investigations of the GUT… (2314685), from National Science Foundation, on March 15, 2024.
On GovTribe
See Biomesense Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors